Within a COST action (BM0607), a number of different radiolabelled minigastrin analogues targeting CCK2R were tested preclinically and compared in a concerted effort to develop a new radiopharmaceutical for diagnosis and treatment of MTC. The gene discussed is CCKBR; the disease is medullary thyroid gland carcinoma.